Novo Nordisk seeks U.S., European approval of diabetes drug

05/27/2008 | Bloomberg

Danish firm Novo Nordisk is seeking marketing approval for diabetes treatment liraglitude in the U.S. and Europe in a bid to launch the drug next year. Liraglitude is expected to compete with similar drugs being developed by Sanofi-Aventis and Novartis. The drug is based on glucagon-like peptide-1, a hormone that activates insulin production in the pancreas.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC